World Vaccine Congress

Safety and adverse event monitoring don't stop when a vaccine is approved.

Investigators face several technical, logistical, and cultural challenges when conducting vaccine trials in developing nations.

Although the market is growing, vaccine makers face a variety of technical, research, and business challenges.

Virus-like particles have been used in approved vaccines and several prophylactic and therapeutic vaccine candidates in clinical development.

Ensuring the safety of patients in vaccine clinical trials requires close cooperation between sponsors and vaccine suppliers.

As vaccine manufacturers turn their focus to emerging markets, several technical and logistic hurdles remain to be overcome.

Vaccine that incorporates nanoparticles filled with potent stimulators of the innate immune system proves promising in clinical trials.

Clinicians will need new materials and technologies as medicine becomes more personalized.

A successful government-industry collaboration produced a safer preventive vaccine against this deadly disease.

New vaccine would be the first cell-derived, recombinant protein-based influenza vaccine licensed in the US.

Early positive clinical trial results for a novel nasal influenza vaccine.

Vaccine expert says that there are many lessons to be learned from the response to the most recent H1N1 pandemic.

Researchers studying influenza vaccines were able to achieve immune response with a single vaccination against H1N1.

How a massive operation of medical countermeasures was mobilized to tackle the ever-present threat of influenza in the US and overseas.

Safe and effective new nasal spray-delivered influenza vaccine could be produced quickly in high quantities during a pandemic infection.

The World Vaccine Congress Lyon is the premiere vaccine conference addressing all major vaccine markets.